Statin utilization according to indication and age: A Danish cohort study on changing prescribing and purchasing behaviour

Health Policy

Volumn 108, Issue 2-3, 2012, Pages 216-227

  Wallach Kildemoes, Helle ^a   Vass, Mikkel ^a   Hendriksen, Carsten ^a   Andersen, Morten ^b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Drivers; Guidelines; Indications; Prescribing behaviour; Prices; Purchasing behaviour; Statin utilization

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; DENMARK; DRUG USE; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRESCRIPTION; PREVALENCE; PURCHASING; REGISTER; TREATMENT INDICATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ASYMPTOMATIC DISEASES; CORONARY DISEASE; DELIVERY OF HEALTH CARE; DENMARK; DRUG COSTS; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHYSICIAN'S PRACTICE PATTERNS; POISSON DISTRIBUTION; PREVALENCE;

EID: 84870063501     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2012.08.008     Document Type: Article

References (94)

1. Walley T., Folino-Gallo P., Stephens P., Van G.E. Trends in prescribing and utilization of statins and other lipid lowering drugs across Europe 1997-2003. British Journal of Clinical Pharmacology 2005, 60(5):543-551.
2. Kildemoes H.W., Stovring H., Andersen M. Driving forces behind increasing cardiovascular drug utilization: a dynamic pharmacoepidemiological model. British Journal of Clinical Pharmacology 2008, 66(6):885-895.
3. Walley T., Folino-Gallo P., Schwabe U., Van G.E. Variations and increase in use of statins across Europe: data from administrative databases. British Medical Journal 2004, 328(7436):385-386.
4. Teeling M., Bennett K., Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. British Journal of Clinical Pharmacology 2005, 59(2):227-232.
5. Dubois R.W., Dean B.B. Evolution of clinical practice guidelines: evidence supporting expanded use of medicines. Disease Management 2006, 9(4):210-223.
6. Petursson H., Getz L., Sigurdsson J.A., Hetlevik I. Can individuals with a significant risk for cardiovascular disease be adequately identified by combination of several risk factors? Modelling study based on the Norwegian HUNT 2 population. Journal of Evaluation in Clinical Practice 2009, 15(1):103-109.
7. Brugts J.J., Deckers J.W. Statin prescription in men and women at cardiovascular risk: to whom and when?. Current Opinion in Cardiology 2010, 25(5):484-489.
8. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344(8934):1383-1389.
9. Ong H.T. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. The Quarterly Journal of Medicine 2005, 98(8):599-614.
10. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of the American Medical Association 2001, 285(19):2486-2497.
11. De Backer G., Ambrosioni E., Borch-Johnsen K., Brotons C., Cifkova R., Dallongeville J., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other societies on cardiovascular disease prevention in clinical practice. European Heart Journal 2003, 24(17):1601-1610.
12. Graham I.M. Guidelines on cardiovascular disease prevention in clinical practice: the European perspective. Current Opinion in Cardiology 2005, 20(5):430-439.
13. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). European Heart Journal 2007, 28(19):2375-2414.
14. De Backer G. New European guidelines for cardiovascular disease prevention in clinical practice. Clinical Chemistry and Laboratory Medicine 2009, 47(2):138-142.
15. Christensen B., Heebøll-Nielsen N., Madsen L., Lous J., Færgemann O., Stender S., et al. Forebyggelse af iskæmisk hjertesygdom i almen praksis - med særligt henblik på dyslipidæmi: En klinisk vejledning 1998, The Danish College of General Practitioners (DSAM), Aalborg.
16. Christensen B., Færgemann O., Heebøll-Nielsen N., Lous J., Madsen L.D., Stender S. Forebyggelse af iskæmisk hjertekarsygdom i almen praksis. En klinisk vejledning (2) 2002, The Danish College of General Practitioners (DSAM), Denmark.
17. Brugts J.J., Yetgin T., Hoeks S.E., Gotto A.M., Shepherd J., Westendorp R.G., et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. British Medical Journal 2009, 338:b2376.
18. Kostis W.J., Cheng J.Q., Dobrzynski J.M., Cabrera J., Kostis J.B. Meta-analysis of statin effects in women versus men. Journal of the American College of Cardiology 2012, 59(6):572-582.
19. Tonelli M., Lloyd A., Clement F., Conly J., Husereau D., Hemmelgarn B., et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. Canadian Medical Association Journal 2011, 183(16):E1189-E1202.
20. Ray K.K., Seshasai S.R., Erqou S., Sever P., Jukema J.W., Ford I., et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Archives of Internal Medicine 2010, 170(12):1024-1031.
21. Petretta M., Costanzo P., Perrone-Filardi P., Chiariello M. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. International Journal of Cardiology 2010, 138(1):25-31.
22. Raymond C.B., Morgan S.G., Katz A., Kozyrskyj A.L. A population-based analysis of statin utilization in British Columbia. Clinical Therapeutics 2007, 29(9):2107-2119.
23. Savoie I., Kazanjian A. Utilization of lipid-lowering drugs in men and women. A reflection of the research evidence?. Journal of Clinical Epidemiology 2002, 55(1):95-101.
24. Ruokoniemi P., Helin-Salmivaara A., Klaukka T., Neuvonen P.J., Huupponen R. Shift of statin use towards the elderly in 1995-2005: a nation-wide register study in Finland. British Journal of Clinical Pharmacology 2008, 66(3):405-410.
25. Selmer R., Sakshaug S., Skurtveit S., Furu K., Tverdal A. Statin treatment in a cohort of 20,212 men and women in Norway according to cardiovascular risk factors and level of education. British Journal of Clinical Pharmacology 2009, 67(3):355-362.
26. Jackevicius C.A., Tu K., Filate W.A., Brien S.E., Tu J.V. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Canadian Journal of Cardiology 2003, 19(12):1359-1366.
27. Dubois R.W., Alexander C.M., Wade S., Mosso A., Markson L., Lu J.D., et al. Growth in use of lipid-lowering therapies: are we targeting the right patients?. American Journal of Managed Care 2002, 8(10):862-867.
28. Feely J., McGettigan P., Kelly A. Growth in use of statins after trials is not targeted to most appropriate patients. Clinical Pharmacology and Therapeutics 2000, 67(4):438-441.
29. Abramson J., Wright J.M. Are lipid-lowering guidelines evidence-based?. Lancet 2007, 369(9557):168-169.
30. Golomb B.A., Evans M.A. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. American Journal of Cardiovascular Drugs 2008, 8(6):373-418.
31. Bjerrum L., Larsen J., Kragstrup J. Guidelines accompanied by changes in reimbursement rules. Effects on lipid-lowering drug prescribing. Scandinavian Journal of Primary Health Care 2001, 19(3):158-162.
32. The Danish Medicines Agency Medicine sales in Denmark 2011, [accessed 21.11.11]. http://www%20medstat%20dk/en.
33. Rasmussen J.N., Gislason G.H., Abildstrom S.Z., Rasmussen S., Gustafsson I., Buch P., et al. Statin use after acute myocardial infarction: a nationwide study in Denmark. British Journal of Clinical Pharmacology 2005, 60(2):150-158.
34. Thygesen L.C., Daasnes C., Thaulow I., Bronnum-Hansen H. Introduction to Danish (nationwide) registers on health and social issues: structure, access, legislation and archiving. Scandinavian Journal of Public Health 2011, 39(Suppl. 7):12-16.
35. Wallach-Kildemoes H., Hendriksen C., Andersen M. Drug utilization according to reason for prescribing: a pharmacoepidemiologic method based on an indication hierarchy. Pharmacoepidemiology and Drug Safety 2011, Epub ahead of print.
36. Strandberg-Larsen M, Nielsen M, Vallgårda S, Krasnik A, Vrangbæk K. Health system review. Denmark: World Health Organisation, on behalf of the European Observatory on Health Systems and Policies; 2007.
37. Donaldson C., Gerard K. Economics of health care financing: the visible hand 1993, Macmillan Press Ltd., London. 1st ed.
38. Vallgaarda S., Krasnik A. Sundhedsvæsen og sundhedspolitik 2010, Munksgaard, Copenhagen. 2nd ed.
39. Pedersen K.M. Pricing and reimbursement of drugs in Denmark. The European Journal of Health Economics 2003, 460-465.
40. Thomsen T., Christensen B., Hildebrant P., Iversen H.K., Lytken-Larsen M., Sillesen H., et al. Kliniske retningslinier for forebyggelse af kardiovaskulær sygdom i Danmark 2004, European Society of Cardiology, Denmark.
41. Conroy R.M., Pyorala K., Fitzgerald A.P., Sans S., Menotti A., De Backer G., et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal 2003, 24(11):987-1003.
42. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine 1996, 335(14):1001-1009.
43. Miettinen T.A., Pyorala K., Olsson A.G., Musliner T.A., Cook T.J., Faergeman O., et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997, 96(12):4211-4218.
44. Hebert P.R., Gaziano J.M., Chan K.S., Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. The Journal of the American Medical Association 1997, 278(4):313-321.
45. Haffner S.M., Alexander C.M., Cook T.J., Boccuzzi S.J., Musliner T.A., Pedersen T.R., et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Archives of Internal Medicine 1999, 159(22):2661-2667.
46. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. The Journal of the American Medical Association 1998, 279(20):1615-1622.
47. Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. American Journal of Cardiology 1995, 76(9):113C-117C.
48. Caro J., Klittich W., McGuire A., Ford I., Norrie J., Pettitt D., et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. British Medical Journal 1997, 315(7122):1577-1582.
49. Pyorala K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994, 110(2):121-161.
50. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998, 140(2):199-270.
51. Thomassen A., Færgemann O., Grande P., Haghfelt T., Kristensen BØ, Larsen M.L., et al. Den dyslipidæmiske hjertepatient. Klaringsrapport fra Dansk Cardiologisk Selskab. The Journal of the Danish Medical Association 1996, 158(Suppl. 1):1-14.
52. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360(9326):7-22.
53. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360(9346):1623-1630.
54. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). The Journal of the American Medical Association 2002, 288(23):2998-3007.
55. Færgemann O., Christensen B., Hansen H.S., Jensen G.B., Melchior T.M., Nordestgaard B.G., et al. Sekundær og primær forebyggelse af koronar hjertesygdom med særligt henblik på dyslipidæmi 2000, Danish Society of Cardiology (DSC), Denmark.
56. Thomsen T.F., Davidsen M., Ibsen H., Jorgensen T., Jensen G., Borch-Johnsen K. A new method for CHD prediction and prevention based on regional risk scores and randomized clinical trials: PRECARD and the Copenhagen Risk Score. Journal of Cardiovascular Risk 2001, 8(5):291-297.
57. Hoffmann M. Store prisfald på vej. Farmaci 2003, 1028-1029.
58. Shepherd J., Barter P., Carmena R., Deedwania P., Fruchart J.C., Haffner S., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006, 29(6):1220-1226.
59. Mora S., Ridker P.M. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) - can C-reactive protein be used to target statin therapy in primary prevention?. American Journal of Cardiology 2006, 97(2A):33A-41A.
60. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005, 91(Suppl. 5). v1-52.
61. Hirsch A.T., Haskal Z.J., Hertzer N.R., Bakal C.W., Creager M.A., Halperin J.L., et al. ACC/AHA Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Journal of Vascular and Interventional Radiology 2006, 17(9):1383-1397.
62. Type 2-diabetes: a Danish Medical Technology Assessment of screening, diagnostics and treatment 2003, Sundhedsstyrelsen, Center for Evaluering og Medicinsk Teknologivurdering, Copenhagen.
63. Ward S., Lloyd J.M., Pandor A., Holmes M., Ara R., Ryan A., et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technology Assessment 2007, 11(14). 1-iv.
64. Thavendiranathan P., Bagai A., Brookhart M.A., Choudhry N.K. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Archives of Internal Medicine 2006, 166(21):2307-2313.
65. Petersen L.K., Christensen K., Kragstrup J. Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds. Age and Ageing 2010, 39(6):674-680.
66. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 2007, 194(1):1-45.
67. Christensen B., Færgemann O., Heebøll-Nielsen N., Lous J., Madsen L.D., Stender S. Forebyggelse af iskæmisk hjertekarsygdom i almen praksis. En klinisk vejledning (3) 2007, The Danish College of General Practitioners (DSAM), Denmark.
68. Ridker P.M., Macfadyen J.G., Fonseca F.A., Genest J., Gotto A.M., Kastelein J.J., et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation: Cardiovascular Quality and Outcomes 2009, 2(6):616-623.
69. IRF Bivirkninger ved statiner? 2008, Danish Institute for Rational Pharmacotherapy, [accessed 30.11.11]. http://www.irf.dk/dk/nyheder/arkiv/bivirkninger_ved_statin-htm.
70. Jensen H.K. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark. Danish Medical Bulletin 2002, 49(4):318-345.
71. DeWilde S., Carey I.M., Bremner S.A., Richards N., Hilton S.R., Cook D.G. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism?. Heart 2003, 89(4):417-421.
72. Golomb B.A. Implications of statin adverse effects in the elderly. Expert Opinion on Drug Safety 2005, 4(3):389-397.
73. Scott D., Blizzard L., Fell J., Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. The Quarterly Journal of Medicine 2009, 102(9):625-633.
74. Robinson J.G. Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges. Drugs and Aging 2009, 26(11):917-931.
75. Fedder D.O., Koro C.E., L'Italien G.J. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation 2002, 105(2):152-156.
76. Getz L., Sigurdsson J.A., Hetlevik I., Kirkengen A.L., Romundstad S., Holmen J. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. British Medical Journal 2005, 331(7516):551.
77. Tunstall-Pedoe H., Woodward M. By neglecting deprivation, cardiovascular risk scoring will exacerbate social gradients in disease. Heart 2006, 92(3):307-310.
78. Diederichsen A.C., Sand N.P., Norgaard B., Lambrechtsen J., Jensen J.M., Munkholm H., et al. Discrepancy between coronary artery calcium score and HeartScore in middle-aged Danes: the DanRisk study. European Journal of Cardiovascular Prevention and Rehabilitation 2011, Epub ahead of print.
79. Law M.R., Wald N.J., Morris J.K. The performance of blood pressure and other cardiovascular risk factors as screening tests for ischaemic heart disease and stroke. Journal of Medical Screening 2004, 11(1):3-7.
80. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. European Heart Journal 1997, 18(11):1718-1724.
81. Bodenheimer T., Wagner E.H., Grumbach K. Improving primary care for patients with chronic illness: the chronic care model. Part 2. The Journal of the American Medical Association 2002, 288(15):1909-1914.
82. Frolich A., Hendriksen C., Jorgensen S.J. Optimization of the care process for chronic diseases: the Chronic Care Model. Ugeskrift for Laeger 2005, 167(3):266-268.
83. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyorala K. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Journal of Hypertension 1998, 16(10):1407-1414.
84. Durrington P.N. Diabetic dyslipidaemia. Bailliere's Best Practice and Research. Clinical Endocrinology and Metabolism 1999, 13(2):265-278.
85. Krasnik A., Groenewegen P.P., Pedersen P.A., von S.P., Mooney G., Gottschau A., et al. Changing remuneration systems: effects on activity in general practice 2. British Medical Journal 1990, 300(6741):1698-1701.
86. Giacomini M.K., Cook D.J., Streiner D.L., Anand S.S. Using practice guidelines to allocate medical technologies - an ethics framework. International Journal of Technology Assessment in Health Care 2000, 16(4):987-1002.
87. Dans A.M., Dans L., Oxman A.D., Robinson V., Acuin J., Tugwell P., et al. Assessing equity in clinical practice guidelines. Journal of Clinical Epidemiology 2007, 60(6):540-546.
88. Weinstein M.C. Should physicians be gatekeepers of medical resources?. Journal of Medical Ethics 2001, 27(4):268-274.
89. Garfield F.B., Garfield J.M. Clinical judgment and clinical practice guidelines. International Journal of Technology Assessment in Health Care 2000, 16(4):1050-1060.
90. Grilli R., Magrini N., Penna A., Mura G., Liberati A. Practice guidelines developed by specialty societies: the need for a critical appraisal. Lancet 2000, 355(9198):103-106.
91. Savoie I., Kazanjian A., Bassett K. Do clinical practice guidelines reflect research evidence?. Journal of Health Services Research and Policy 2000, 5(2):76-82.
92. Mantel-Teeuwisse A.K., Klungel O.H., Hofman A., Verschuren W.M., Trienekens P.H., Porsius A.J., et al. Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999). British Journal of Clinical Pharmacology 2006, 61(5):592-600.
93. Manuel D.G., Kwong K., Tanuseputro P., Lim J., Mustard C.A., Anderson G.M., et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study. British Medical Journal 2006, 332(7555):1419.
94. McElduff P., Jaefarnezhad M., Durrington P.N. American, British and European recommendations for statins in the primary prevention of cardiovascular disease applied to British men studied prospectively. Heart 2006, 92(9):1213-1218.